Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Repurchased
Ratios

Tonix Pharmaceuticals Holding (TNXP) Accumulated Depreciation & Amortization: 2023-2025

Historic Accumulated Depreciation & Amortization for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $5.5 million.

  • Tonix Pharmaceuticals Holding's Accumulated Depreciation & Amortization rose 53.72% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.3 million, marking a year-over-year increase of 4.94%. This contributed to the annual value of $4.1 million for FY2024, which is 23.59% down from last year.
  • Tonix Pharmaceuticals Holding's Accumulated Depreciation & Amortization amounted to $5.5 million in Q3 2025, which was up 9.09% from $5.1 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Accumulated Depreciation & Amortization high stood at $6.3 million for Q1 2024, and its period low was $2.5 million during Q1 2023.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's median Accumulated Depreciation & Amortization value was $4.4 million (recorded in 2023), while the average stood at $4.4 million.
  • Per our database at Business Quant, Tonix Pharmaceuticals Holding's Accumulated Depreciation & Amortization soared by 148.78% in 2024 and then fell by 27.53% in 2025.
  • Tonix Pharmaceuticals Holding's Accumulated Depreciation & Amortization (Quarterly) stood at $5.4 million in 2023, then declined by 23.59% to $4.1 million in 2024, then skyrocketed by 53.72% to $5.5 million in 2025.
  • Its Accumulated Depreciation & Amortization was $5.5 million in Q3 2025, compared to $5.1 million in Q2 2025 and $4.6 million in Q1 2025.